Hypertriglyceridaemia: Diagnostics, risk and treatment;Hypertriglyseridemi - Diagnostikk, risiko og behandling

Tidsskrift for den Norske Laegeforening

Volumn 124, Issue 21, 2004, Pages 2746-2749

  Hexeberg, Sofie ^a   Retterstøl, Kjetil ^b  

^a Statens Legemiddelverk   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; COLESEVELAM; CREATININE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; GEMFIBROZIL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; REPAGLINIDE; THYROTROPIN; ANTILIPEMIC AGENT; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; NICOTINIC ACID DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIET THERAPY; EATING DISORDER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREATITIS; PREGNANCY; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASE; FEMALE; MALE; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MALE; NICOTINIC ACIDS; PREGNANCY; RISK FACTORS;

EID: 14644401804     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Jeppesen J, Hein HO, Suadicani P et al. Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029-36.
2. Toskes PP. Hyperlipemic pancreatitis. Gastroenterol Clin North Am 1990; 19: 783-91.
3. Assmann G, Schulte H, Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-84.
4. Stampfer MJ, Krauss RM, Ma J et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882-8.
5. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9.
6. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45.
7. Manninen V, Olli EM, Heikki FM et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641-51.
8. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992; 85: 37-45.
9. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezatibrate Infarction Prevention (BIP) Study. Circulation 2000; 102: 21-7.
10. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8.
11. Ballantyne CM, Olsson AG, Cook TJ et al for the Scandinavian Simvastatin Survival Study (4S) Group. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104: 3046-51.
12. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
13. Shepherd J, Cobbe SM, Ford J et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
14. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199-270.
15. Miller M, Seidler A, Moalemi A et al. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 1998; 31: 1252-7.
16. Terapianbefaling fra Statens legemiddelverk. Behandling med lipidsenkende legemidler for å forebygge hierte- og karsykdom. www.legemiddelverket.no/ terapi/publisert/hyperlipidemi.htm (2003).
17. Staels B, Dallongeville J, Auwerx J et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-93.
18. Fruchart J-C, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001; 3: 83-92.
19. Retterstøl K. Hypertriglyseridemi. Hjerte- og karsykdommer i praksis 2000; 4: 1-4.
20. Statens legemiddelverk. Ny kontraindikasjon: NovoNorm skal ikke brukes sammen med gemfibrozil. www.legemiddelverket.no/bivirk/prepfok/ NovoNorm.htm (28.5.2003).
21. Statens legemiddelverk. Statiner: Nye retningslinjer for kontroll av pasienter.www.legemiddelverket.no/bivirk/prepfok/statiner.htm (5.6.2002).
22. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-55.